the BCR-ABL gene You might see the BCR-ABL1 gene written in a more scientific way BCR::ABL1. Genetic tests are also done to look for other abnormal chromosomes . You might hear these tests called ...

The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in ...

It will detect the BCR-ABL1 gene for many months after you start treatment. So it can take a long time to have a deep molecular response. There are national guidelines for 'target' PCR results at ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers ...

Asciminib shows superior tolerability over nilotinib in newly diagnosed CML-CP patients, reducing treatment discontinuation ...

Fusions involving kinases first emerged as significant, clinically relevant treatment targets with the discovery that the BCR-ABL1 encoded fusion, which is pathognomonic to chronic myeloid leukemia, ...

A total of 43 patients with HLRCC-associated papillary renal-cell carcinoma and 40 patients with sporadic papillary renal-cell carcinoma were enrolled. A confirmed response occurred in 31 patients ...